Can Retatrutide Cause UTI? Trial Evidence

Retatrutide is an investigational triple receptor agonist developed by Eli Lilly, targeting GLP-1, GIP and glucagon receptors. It holds no marketing authorisation in the UK or elsewhere and is available only within authorised clinical trials. Questions about whether retatrutide can cause urinary tract infections (UTIs) have arisen from Phase 2 trial safety data, where UTIs were recorded among adverse events. This article summarises what the current trial evidence shows, which participants may be at higher baseline UTI risk, and what the broader safety profile looks like based on published data.

What is retatrutide and what is its current UK regulatory status?

Retatrutide is an investigational triple receptor agonist (GLP-1, GIP and glucagon) with no UK marketing authorisation; it is available only within authorised clinical trials, and no MHRA or NICE assessment for routine use exists.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it can be prescribed or supplied only within an authorised clinical trial.^[8][1] It is an investigational medicine developed by Eli Lilly that acts as a triple receptor agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors simultaneously. This triple mechanism is intended to influence appetite regulation, energy expenditure and glucose metabolism, though its clinical effects have so far been evaluated only in trial settings.

Because retatrutide has no UK marketing authorisation, the Medicines and Healthcare products Regulatory Agency (MHRA) has not assessed it for routine clinical use, and no National Institute for Health and Care Excellence (NICE) guidance exists for it. The evidence base currently comes from named clinical trials, including Phase 2 data published in the New England Journal of Medicine and the ongoing Phase 3 TRIUMPH and TRANSCEND programmes. These trials are the only legitimate context in which the medicine is available.

Anyone who encounters retatrutide being sold online outside a clinical trial should be aware that such a product is not a licensed medicine and may be falsified or unsafe. If you are interested in licensed weight-management treatments, a GP can discuss options that are currently authorised and available through appropriate clinical pathways.

What urinary side effects have been reported in clinical trials?

UTIs were recorded in the Phase 2 trial safety data (Jastreboff et al., 2023), but published evidence does not confirm a causal relationship, and precise event counts for UTIs were not reported in the main trial text.

Urinary tract infections (UTIs) have been reported among participants in retatrutide clinical trials, though the available published data do not establish a definitive causal relationship between the medicine and UTI occurrence. In the Phase 2 trial reported in the New England Journal of Medicine (Jastreboff et al., 2023), adverse events were recorded across dose groups and placebo, and urinary tract infections appeared in the safety data. The published report does not provide precise event counts for UTIs in the main text, and the finding should be understood as qualitative rather than quantitative at this stage.

Some researchers have speculated that the glucagon receptor agonist component of retatrutide could theoretically influence renal function or urine composition, but this mechanism has not been confirmed in published trial data for retatrutide specifically. Any comparison with the glycosuria seen with sodium-glucose cotransporter-2 (SGLT-2) inhibitors is hypothetical: the pharmacological mechanisms differ, and no published source has established a comparable effect for retatrutide. This question remains open and will require data from larger, longer-term studies to address.

It is also worth noting that participants in retatrutide trials include people with obesity and, in some arms, type 2 diabetes, both of which are independently associated with higher UTI risk. Separating a medicine-related signal from background risk in these populations requires larger, longer-term studies. The TRIUMPH and TRANSCEND Phase 3 programmes are expected to generate more detailed safety data, including on urinary adverse events, as results continue to be reported.

Who may be at higher risk of urinary tract infections during trials?

Women, people with type 2 diabetes, older adults and those with a history of recurrent UTIs carry higher baseline UTI risk regardless of the medicine, making it difficult to attribute urinary events specifically to retatrutide.

Certain groups of trial participants may face a higher baseline risk of urinary tract infections regardless of the medicine being studied. Women are significantly more susceptible to UTIs than men due to anatomical differences, including a shorter urethra, which allows bacteria easier access to the bladder.^[7] This biological vulnerability means that female participants in retatrutide trials may report UTIs at higher rates, a pattern consistent with UTI epidemiology in the general population rather than necessarily reflecting a drug-specific effect.

People living with type 2 diabetes represent another higher-risk group. Poorly controlled blood glucose can impair immune function and promote bacterial growth in the urinary tract, making diabetic individuals more prone to both uncomplicated and complicated UTIs.^[9][10] Some retatrutide trial arms have enrolled participants with type 2 diabetes, and this must be considered when interpreting urinary adverse event rates in those cohorts.

Older adults, those with a history of recurrent UTIs, urinary tract abnormalities, catheterisation or reduced fluid intake, and those who are immunosuppressed may also carry elevated baseline risk. Trial eligibility criteria typically exclude participants with active infections at enrolment, but incident infections during the study period remain possible in any of these subgroups.

If you are enrolled in an authorised retatrutide trial and develop possible UTI symptoms, you should contact your trial team promptly under the study protocol. Symptoms that require same-day or urgent assessment include fever, shivering or rigors, pain in the lower back or sides (flank pain), vomiting, new confusion (particularly in older adults) or any signs suggesting sepsis. Men with a suspected UTI and pregnant people with any urinary symptoms should also seek prompt clinical assessment, as these groups are at higher risk of complications.^[7] If you attend an emergency department or urgent care setting, inform the clinician that you are enrolled in a clinical trial and carry your trial documentation with you. For non-urgent concerns, contact your GP; for urgent advice outside trial hours, NHS 111 is available. Suspected side effects from a medicine you are taking outside a clinical trial can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk; if you are in a trial, report adverse events to your trial team or study sponsor as directed by the protocol.

What does the current evidence say about retatrutide's safety profile?

Phase 2 data show gastrointestinal effects as the most common adverse events; UTIs were also recorded, but a full benefit-risk assessment has not been completed by any regulatory body, including the MHRA.

The current evidence on retatrutide's safety profile is derived from Phase 2 trial data and early Phase 3 reporting, and it should be interpreted with the limitations of these sources in mind. In the Phase 2 trial published in the New England Journal of Medicine, the most commonly reported adverse events were gastrointestinal in nature, including nausea, vomiting, diarrhoea and constipation.^[1][2] These are consistent with the GLP-1 receptor agonist component of the medicine and are a recognised class effect seen with authorised GLP-1 medicines such as semaglutide and liraglutide.^[5][6]

Beyond gastrointestinal effects, the trial safety data included a range of other adverse events across organ systems, with urinary tract infections among those recorded. The UK SmPCs for authorised GLP-1 receptor agonists note that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome; no risk magnitude is established in those documents.^[5] Whether retatrutide carries a comparable signal will require assessment from larger, longer-duration data sets, and no such conclusion can be drawn from Phase 2 data alone.

Retatrutide trials exclude participants who are pregnant, breastfeeding or planning pregnancy, reflecting the absence of safety data in these groups. Women of childbearing potential participating in trials are required to use effective contraception throughout. These exclusions mean that safety data in pregnant or lactating individuals are not available, and the medicine's effects in these groups remain unknown.

Because retatrutide is not authorised, no UK regulatory body has completed a full benefit-risk assessment. The TRIUMPH and TRANSCEND Phase 3 programmes will provide substantially more safety data across larger populations and longer timeframes, and any future regulatory submission would be evaluated by the MHRA on the basis of that complete evidence package.

Frequently Asked Questions